Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators

Author(s): Malik Hamaidia, Bernard Staumont, Bernard Duysinx, Renaud Louis, Luc Willems.

Journal Name: Current Topics in Medicinal Chemistry

Volume 16 , Issue 7 , 2016

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

In the absence of a satisfactory treatment of malignant pleural mesothelioma (MPM), novel therapeutic strategies are urgently needed. Among these, immunotherapy offers a series of advantages such as tumor specificity and good tolerability. Unfortunately, MPM immunotherapy is frequently limited by incomplete cell differentiation or feedback loop regulatory mechanisms. In this review, we describe different components of the innate immune system and discuss strategies to improve MPM immunotherapy by using epigenetic modulators.

Keywords: Cancer, Epigenetic inhibitors, Histone deacetylase, Immunotherapy, Malignant pleural mesothelioma.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 7
Year: 2016
Page: [777 - 787]
Pages: 11
DOI: 10.2174/1568026615666150825141152
Price: $58

Article Metrics

PDF: 26
HTML: 1
EPUB: 1
PRC: 1